Biohaven Q2 net loss $90.3M; cash $349M; FDA refuses SCA3 NDA; pipeline advances

Biohaven Ltd.

2023-Q2 EPS reported -$2.36

Net loss $90.3M ($1.32/sh) vs $203.3M ($5.16/sh) in Q2 2022; adjusted net loss $85.7M ($1.25/sh).
Cash and marketable securities $349.0M as of June 30, 2023, down from $467.9M at Dec 31, 2022.
BHV-7000 Kv7 activator showed CNS target engagement without somnolence; Phase 2/3 in epilepsy and bipolar disorder planned 2H 2023.
FDA refused to file troriluzole NDA for SCA3; Biohaven plans Type A meeting to address FDA concerns.
BHV-8000 (TYK2/JAK1) Phase 1 SAD dosed, well tolerated; Phase 2 in Parkinson's disease planned 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biohaven Ltd. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.

View on SEC.gov

Browse all earnings releases →

Biohaven Ltd. filing history →

Source: SEC EDGAR

accession 0001935979-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.